Update shared on 27 Nov 2025
Fair value Increased 3.15%Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.
Analyst Commentary
Recent analysis of 10x Genomics reveals a nuanced outlook among industry experts, reflecting both confidence in the company's strengths and caution regarding its current challenges. The following summarizes key points raised by analysts:
Bullish Takeaways- Bullish analysts highlight the company’s leadership position in single-cell technology. They note its extensive installed base and technological edge over competitors as important differentiators that support long-term valuation.
- The recent purchase of a sizable stake by a major institutional investor is viewed as a positive signal of confidence in the company's future growth prospects.
- Analysts anticipate that ongoing investment and innovation will help the company capitalize on future opportunities in the life sciences and research markets.
- Expectations of improved revenue growth, even amidst macroeconomic uncertainty, underscore the resilience of the company's underlying business model.
- Bearish analysts express caution about near-term execution. They recommend patience as the company navigates a challenging macroeconomic environment that could weigh on demand.
- There is concern that, despite technical leadership, current conditions may limit the company's ability to translate its strong market position into immediate financial returns.
- The need for demonstrable, sustained growth in key revenue segments remains a critical factor for upward revision in valuation estimates.
What's in the News
- Cathie Wood's ARK Investment purchased 222,000 shares of 10x Genomics, signaling continued institutional interest (Periodicals).
- 10x Genomics announced a collaboration with the Garvan Institute of Medical Research and the University of Tokyo to create a comprehensive pan-cancer spatial atlas for the Asia-Pacific region using its Xenium spatial platform (Key Developments).
- The company launched the next generation of its Flex assay, introducing automation-compatible plate-based multiplexing to enable scalable and cost-effective single cell analysis (Key Developments).
- 10x Genomics provided fourth quarter 2025 revenue guidance, projecting $154 million to $158 million in revenue. This reflects a 6% year-over-year decline and sequential quarterly growth (Key Developments).
- A new collaboration has begun between 10x Genomics and CLISEQ Ltd. on the PERIBLOOD clinical trial. This project aims to validate peripheral single cell RNA sequencing as a minimally invasive diagnostic for hematologic disorders across a global cohort (Key Developments).
Valuation Changes
- Fair Value Estimate has risen slightly, increasing from $15.86 to $16.36 per share.
- Discount Rate has edged up modestly from 7.81% to 7.83%.
- Revenue Growth Forecast has increased from 2.70% to 3.20%.
- Net Profit Margin projection has fallen marginally from 15.70% to 15.51%.
- Future P/E Ratio expectation has gone up from 25.32x to 26.25x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.